在Sjögren干眼病中,S100A8/A9通过调节Acod1/STAT3通路来促进树突细胞介导的Th17细胞反应
Yankai Wei1, Mei Sun1, Xinyu Zhang1
1Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.
Investigative ophthalmology & visual science
|January 14, 2025
概括
斯约格伦干眼病 (SjDED) 涉及S100A8/A9升高,通过Acod1/STAT3通路驱动炎症. 用帕基尼莫德抑制这种途径显示了SjDED的治疗潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 眼科医生 眼科 眼科
- 分子生物学分子生物学
背景情况:
- 斯约格伦干眼病 (SjDED) 是一种自身免疫性疾病,其特征是眼睛表面炎症.
- 在SjDED病原体中S100A8/A9的作用需要进一步阐明.
研究的目的:
- 调查S100A8 / A9在SjDED病变发生中的作用.
- 探索SjDED中S100A8/A9作用的潜在机制.
- 评估针对S100A8/A9.9.的治疗潜力.
主要方法:
- S100A8/A9表达分析通过西部斑块和qRT-PCR.
- 帕基尼莫德是一种S100A8/A9抑制剂,在SjDED的非肥胖糖尿病 (NOD) 小鼠模型中进行了测试.
- 免疫细胞透,细胞因子水平和分子通路 (STAT3,Acod1) 通过免疫光学,流细胞计,ELISA和ChIP进行评估.
主要成果:
- 在SjDED患者和小鼠中,S100A8/A9的调节升高,与疾病严重程度相关.
- 帕基尼莫德治疗改善了SjDED表型,并减少了Th17细胞比例.
- 在树突细胞中,S100A8/A9通过Acod1/STAT3通路调节了MHC II和Th17极化细胞因子,增强了Th17反应.
结论:
- 在SjDED中,S100A8/A9通过Acod1/STAT3通路促进DC驱动的Th17细胞反应.
- 这种S100A8/A9/Acod1/STAT3通路代表了SjDED的潜在治疗标.
相关概念视频
T Cell Types and Functions
946
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
946
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K


